Analyst Price Target is $7.67
▲ +230.46% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Unity Biotechnology in the last 3 months. The average price target is $7.67, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 230.46% upside from the last price of $2.32.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Unity Biotechnology. This rating has held steady since July 2021, when it changed from a Hold consensus rating.
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.